Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz

AIDS Research and Human Retroviruses

Volumn 23, Issue 8, 2007, Pages 988-995

  Borroto Esoda, Katyna ^a   Waters, Joshua M ^a   Bae, Andrew S ^a   Harris, Jeanette L ^a   Hinkle, John E ^a   Quinn, Joseph B ^a   Rousseau, Frank S ^a  

^a GILEAD SCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; EMTRICITABINE; RNA; STAVUDINE;

AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DEOXYCYTIDINE; DIDANOSINE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; STAVUDINE; TREATMENT FAILURE;

EID: 34848887118     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0310     Document Type: Article

References (32)

1. Bartlett JA, DeMasi R, Quinn J, Moxham C, and Rousseau F: Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15(11): 1369-1377.
2. Palella FJ, Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338(13):853-860.
3. Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296(7):827-843.
4. Department of Health and Human Services (DHHS): Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, October 10, 2006. AIDSinfo Web site. Available at: http://AIDSinfo.nih.gov. Accessed October 10, 2006.
5. Richman DD: Drug resistance and its implications in the management of HIV infection. Antiviral Ther 1997;2:41-58.
6. Wainberg M and Friedland G: Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279(24):1977-1983.
7. Stone VE, Jordan J, Toison J, Miller R, and Pilon T: Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: Self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Synd Hum Retrovirol 2004;36(3):808-816.
8. Turner D and Wainberg MA: HlV transmission and primary drug resistance. AIDS Rev 2006;8(1):17-23.
9. Little SJ, Holte S, Routy J-P, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347(6):385-394.
10. Grant RM, Hecht FM, Warmerdam M, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. J Am Med Assoc 2002;288(2):181-188.
11. Vella S and Palmisano L: The global status of resistance to antiretroviral drugs. Clin Infect Dis 2005;41(Suppl. 4):S239-246.
12. Simon V, Vanderhoeven J, Hurley A, et al.: Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16(11):1511-1519.
13. Wegner S, Brodine L, Mascola J, et al.: Prevalence of genotypic and phenotypic resistnace to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 2000;14(8):1009-1015.
14. Yeni PG, Hammer SM, Hirsch MS, et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2004;292(2):251-265.
15. Saag MS, Cahn P, Raffi F, et al.: Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: A randomized trial. J Am Med Assoc 2004;292(2):180-190.
16. DeGruttola V, Dix L, D'Aquila R, et al.: The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther 2000;5(1):41-48.
17. Petropoulos CJ, Parkin NT, Limoli KL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928.
18. Food and Drug Administration/CDER Web site: Guidance for industry: Antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval, October 2002. Available at: http://www.fda.gov/cder/guidance/3647fnl.doc. Accessed September 29, 2003.
19. Bacheler L, Jeffrey S, Hanna G, et al.: Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75(11):4999-5008.
20. Larder BA, Darby G, and Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243(4899):1731- 1734.
21. Richman D and Staszewski S: Practical Guide to HIV Drug Resistance and Its Implications for Antiretroviral Treatment Strategies, 2nd ed. International Medical Press, London, 2000.
22. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, and Heneine W: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 2001;98(24):13907-13912.
23. Kuritzkes DR: A fossil record of zidovudine resistance in transmitted isolates of HIV-1. Proc Natl Acad Sci USA 2001;98(24):13485-13487.
24. Dunn D, Green H, Matthias R, et al.: Prevalence of reduced drug susceptibility in treatment-naive patients in the UK. Paper presented at the XIII International HIV Drug Resistance Workshop, Canary Islands, Spain, 8-12 June, 2004.
25. Fuentes-Romero L, Rodriguez-Diaz R, Viveros-Rogel M, et al.: Genotypic HIV-Drug resistance among newly diagnosed, never treated persons in Mexico. Paper presented at the XII International HIV Drug Resistance Workshop, Canary Islands, Spain, 8-12 June, 2004.
26. Ross LL, Dretler R, Gerondelis P, Rouse EG, Lim ML, and Lanier ER: A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine. AIDS 2006;20(5):787-789.
27. De Ronde A, Van Dooren M, Van Der Hoek L, et al.: Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-reistant virus. J Virol 2001;75(2):595-602.
28. Schinazi RF, McMillan A, Cannon D, et al.: Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992;36(11):2423-2431.
29. Garcia-Lerma JG, MacInnes H, Bennett D, et al.: A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003;77(10):5685-5693.
30. Costagliola D, Descamps D, Calvez V, et al.: Presence of thymidine-associated mutations and response to d4T, abacavir and ddI in the control arm of the Narval ANRS 088 Trial. Paper presented at the 8th Conference on Retrovirus and Opportunistic Infections, 2001, Chicago, IL.
31. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. J Am Med Assoc 2004;292(2):191-201.
32. Ferrer E, Podzamczer D, Arnedo M, et al.: Genotype and phenotype at baseline and a failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis 2003;187(4):687-690.